Ascendis Pharma A/S
YUVIWEL
achondroplasia with open epiphyses
Resolved
130days ago
Approval decision · Feb 27, 2026
What's at stake
A final FDA approval decision on YUVIWEL for achondroplasia with open epiphyses is expected Feb 27, 2026.
Primary source
· SEC 6-K
verified 13h ago
“the U.S. Food & Drug Administration (“FDA”) has granted approval under the FDA’s Accelerated Approval Program for YUVIWEL”